Advertisement
Screener

Gyre Therapeutics, Inc. (GYRE) Graph

GYRE Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $29.11M; Revenue including tax (m); Cost of revenue $2.21M; Research and development (m).
  • 2026-03-31: Revenue $22.52M; Revenue including tax (m); Cost of revenue $1.23M; Research and development $6.74M.
  • 2025-12-31: Revenue $37.20M*; Revenue including tax (m); Cost of revenue $1.74M*; Research and development $4.82M*.
  • 2025-09-30: Revenue $30.56M; Revenue including tax (m); Cost of revenue $1.63M; Research and development $2.36M.

Product or service

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

GYRE revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.PharmaceuticalProducts$29.10MRevenue$29.10MCost of revenue$2.21MOperating expenses$43.46MOperating income-$14.36MOther income, net-$943.00KSelling, general& administrative$7.86MPre-tax income-$14.43MIncome tax-$164.00KNet income-$14.27M

Segment

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

GYRE revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Gyre$8.00KGyre Pharmaceuticals$29.10MRevenue$29.10MCost of revenue$2.21MOperating expenses$43.46MOperating income-$14.36MOther income, net-$943.00KSelling, general& administrative$7.86MPre-tax income-$14.43MIncome tax-$164.00KNet income-$14.27M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$29.11M(m)$2.21M(m)$7.86M$43.46M-$164.00K-$14.27M
2026-03-31$22.52M(m)$1.23M$6.74M(m)$31.87M$621.00K-$18.58M
2025-12-31$37.20M*(m)$1.74M*$4.82M*(m)$40.75M*$1.30M*-$1.32M*
2025-09-30$30.56M(m)$1.63M$2.36M(m)$22.01M$1.69M$5.94M
2025-06-30$29.73M(m)$1.15M$8.35M$7.28M$31.97M$662.00K-$2.24M
2025-03-31$22.06M(m)$894.00K$3.10M(m)$19.79M$901.00K$4.94M
2024-09-30$25.49M(m)$958.00K$2.77M(m)$20.30M$1.07M$2.86M
2024-06-30$25.23M(m)$770.00K$3.35M(m)$21.26M$1.50M$4.54M
2024-03-31$27.17M$27.17M$979.00K$2.18M(m)$18.12M$2.55M$9.94M
2023-09-30$32.04M(m)$1.18M$3.01M(m)$18.09M$3.68M$7.51M
2023-06-30$29.33M(m)$1.08M$3.57M(m)$23.28M$2.08M$3.77M
2023-03-31$24.93M$24.93M$1.13M$2.63M(m)$17.14M$2.05M$4.22M
2022-09-30(m)(m)(m)$803.00K(m)$5.17M$0.00-$4.88M
2022-06-30(m)(m)(m)$1.87M(m)-$51.53M$0.00$51.63M
2022-03-31$794.00K(m)(m)$9.70M(m)$15.49M$0.00-$14.54M
2021-12-31$2.44M*(m)(m)(m)(m)(m)(m)(m)
2021-09-30$2.30M(m)(m)$20.35M(m)$27.53M(m)-$25.24M
2021-06-30$1.13M(m)(m)$15.39M(m)$21.05M(m)-$19.93M
2021-03-31$1.47M(m)(m)$17.01M(m)$23.91M(m)-$22.44M
2020-09-30$893.00K(m)(m)$12.25M(m)$16.99M(m)-$16.03M
2020-06-30$1.66M(m)(m)$12.91M(m)$19.02M(m)-$17.25M
2020-03-31$16.37M(m)(m)$13.26M(m)$21.43M(m)-$4.05M
2019-09-30(m)(m)(m)$9.93M(m)$13.20M(m)-$12.71M
2019-06-30(m)(m)(m)$11.11M(m)$14.38M(m)-$13.78M
2019-03-31(m)(m)(m)$12.03M(m)$15.71M(m)-$15.08M
2018-09-30(m)(m)(m)$5.58M(m)$8.35M(m)-$7.69M
2018-06-30(m)(m)(m)$3.89M(m)$7.11M(m)-$6.48M
2018-03-31$6.00K(m)(m)$3.77M(m)$6.68M(m)-$5.04M
2017-09-30$318.00K(m)(m)$3.81M(m)$6.20M(m)-$5.79M
2017-06-30$111.00K(m)(m)$3.40M(m)$6.05M(m)-$5.88M
2017-03-31(m)(m)(m)$2.06M(m)$4.44M(m)-$4.14M
2016-09-30(m)(m)(m)$3.40M(m)$5.82M(m)-$4.77M
2016-06-30(m)(m)(m)$2.75M(m)$5.02M(m)-$4.83M
2016-03-31(m)(m)(m)$2.29M(m)$4.68M(m)-$3.59M
2015-12-31(m)(m)(m)(m)(m)$4.79M(m)-$5.13M
2015-09-30(m)(m)(m)$1.49M(m)$3.99M(m)-$5.05M
2015-06-30(m)(m)(m)$1.32M(m)$3.06M(m)-$1.72M
2015-03-31$60.00K(m)(m)$1.38M(m)$3.70M$21.00K-$2.86M
2014-12-31$127.00K(m)(m)(m)(m)$2.47M$16.00K*-$1.30M
2014-09-30$25.00K(m)(m)$1.34M(m)$2.19M$11.00K-$1.50M
2014-06-30$36.00K(m)(m)$1.29M(m)$2.51M$45.00K-$2.08M
2014-03-31$87.00K(m)(m)$9.08M(m)$2.16M$3.41M-$1.73M
2013-12-31$93.00K(m)(m)(m)(m)(m)(m)-$13.37M
2013-09-30(m)(m)(m)$10.31M(m)$13.15M(m)-$12.90M
2013-06-30(m)(m)(m)$9.45M(m)$12.49M(m)-$12.37M
2013-03-31$3.54M(m)(m)$8.32M(m)$11.81M(m)-$8.07M
2012-12-31$590.00K(m)(m)(m)(m)(m)(m)-$15.87M
2012-09-30$768.00K(m)(m)$6.43M(m)$8.87M$0.00-$7.88M
2012-06-30$33.65M(m)(m)$12.51M(m)$19.41M$0.00$14.49M
2012-03-31$22.86M(m)(m)$17.80M(m)$20.87M(m)$2.26M
2011-12-31$18.95M(m)(m)(m)(m)(m)(m)-$9.80M
2011-09-30$18.95M(m)(m)$25.44M(m)$28.29M$0.00-$9.05M
2011-06-30$20.74M(m)(m)$20.18M(m)$23.31M$0.00-$2.26M
2011-03-31$38.99M(m)(m)$23.52M(m)$26.69M(m)$12.59M
2010-09-30$21.80M(m)(m)$17.33M(m)$19.38M$257.00K$2.49M
2010-06-30$20.90M(m)(m)$14.12M(m)$15.94M$1.51M$3.78M

Revenue and expense 6 month

Period endRevenueCost of revenueResearch and developmentSelling, general and administrativeOperating expensesIncome taxNet income
2026-06-30$53.53M$3.44M(m)$18.03M$86.86M$385.00K-$32.80M
2025-06-30$60.30M$2.04M$16.44M$15.48M$60.00M$1.56M$5.30M
2024-06-30$52.40M$1.75M$5.54M(m)$39.38M$4.04M$14.50M
2023-06-30$54.26M$2.20M$6.20M(m)$40.42M$4.14M-$2.21M
2022-06-30(m)(m)$11.57M(m)-$36.03M$0.00$37.10M
2021-06-30$2.60M(m)$32.40M(m)$44.95M(m)-$42.37M
2020-06-30$18.02M(m)$26.17M(m)$40.45M(m)-$21.30M
2019-06-30(m)(m)$23.14M(m)$30.09M(m)-$28.86M
2018-06-30$6.00K(m)$7.66M(m)$13.80M(m)-$11.52M
2017-06-30$382.00K(m)$5.48M(m)$10.50M(m)-$10.02M
2016-06-30(m)(m)$5.05M(m)$9.70M(m)-$8.42M
2015-06-30$60.00K(m)$2.71M(m)$6.76M$21.00K-$4.58M
2014-06-30$123.00K(m)$2.54M(m)$4.67M$3.46M-$3.81M
2013-06-30$3.54M(m)$17.77M(m)$24.30M(m)-$20.44M
2012-06-30$56.50M(m)$30.31M(m)$40.28M$0.00$16.75M
2011-06-30$59.74M(m)$43.70M(m)$50.01M$0.00$10.33M
2010-06-30$40.42M(m)$24.73M(m)$28.36M$2.14M$10.58M

Revenue and expense 9 month

Period endRevenueCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$79.39M$3.67M$8.88M$64.35M$3.26M$11.20M
2024-09-30$77.89M$2.71M$8.31M$59.68M$5.12M$17.30M
2023-09-30$86.30M$3.39M$9.21M$58.51M$7.82M-$3.79M
2022-09-30(m)(m)$12.38M-$30.87M$0.00$32.21M
2021-09-30$4.90M(m)$52.75M$72.48M(m)-$67.60M
2020-09-30$18.92M(m)$38.42M$57.45M(m)-$37.33M
2019-09-30(m)(m)$33.07M$43.29M(m)-$41.57M
2018-09-30$6.00K(m)$13.23M$22.14M(m)-$19.22M
2017-09-30$700.00K(m)$9.29M$16.69M(m)-$15.81M
2016-09-30(m)(m)$8.44M$15.53M(m)-$13.20M
2015-09-30(m)(m)$4.19M$10.76M(m)-$9.63M
2014-09-30$148.00K(m)$3.87M$6.85M$3.47M-$5.31M
2013-09-30$3.54M(m)$28.09M$37.44M(m)-$33.34M
2012-09-30$57.27M(m)$36.75M$49.15M$0.00$8.87M
2011-09-30$78.69M(m)$69.15M$78.29M$0.00$1.28M
2010-09-30$62.22M(m)$42.06M$47.75M$2.40M$13.06M

Revenue and expense 12 month

Period endRevenueRevenue including taxCost of revenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$116.59M(m)$5.42M$13.70M$105.10M$4.56M$9.88M
2024-12-31$105.76M$105.76M$3.88M$12.02M$89.59M$5.32M$17.90M
2023-12-31$113.45M$113.45M$4.64M$13.78M$176.04M$8.52M-$85.48M
2022-12-31$102.29M$102.29M$4.79M(m)$88.29M$5.10M$4.31M
2021-12-31$7.34M(m)(m)$68.89M$95.23M(m)-$87.93M
2020-12-31$20.95M(m)(m)$52.98M$78.32M(m)-$56.24M
2019-12-31(m)(m)(m)$43.86M$57.28M(m)-$55.18M
2018-12-31$6.00K(m)(m)$21.47M$33.83M(m)-$30.05M
2017-12-31$1.02M(m)(m)$12.85M$22.84M(m)-$21.56M
2016-12-31(m)(m)(m)$11.55M$20.82M(m)-$16.95M
2015-12-31(m)(m)(m)$5.96M$15.55M(m)-$14.76M
2014-12-31$275.00K(m)(m)$5.27M$9.32M$3.48M-$6.61M
2013-12-31$3.63M(m)(m)$6.56M$10.64M$7.00K-$9.97M
2012-12-31$57.86M(m)(m)$49.09M$66.00M-$101.00K-$7.00M
2011-12-31$97.64M(m)(m)$95.22M$107.38M$0.00-$8.53M
2010-12-31$85.71M(m)(m)$64.55M$72.60M$3.53M$10.90M
2009-12-31$25.06M(m)(m)$40.18M$65.39M-$88.00K-$39.40M

Similar stocks

Stock NameCountryMarket CapPE Ratio
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
GERON CORP (GERN)United States$0.803B-12.14
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78